SCHEMBL10089936

SCHEMBL10089936

Cc1ccc(CNC(=O)c2cc(C#N)cc(C)c2NC(=O)c2cc(Cn3nnc(C(F)(F)F)n3)nn2-c2ccccc2Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 1/20 0.39
CNR1 P21554 5/20 0.38
SLC2A1 P11166 8/20 0.37
SLC2A3 P11169 8/20 0.37
SLC2A4 P14672 8/20 0.37
DHODH Q02127 1/20 0.36
KDM5B Q9UGL1 1/20 0.35
SLC2A2 P11168 3/20 0.35
KLKB1 P03952 2/20 0.35
LMNA P02545 1/20 0.34
ELANE P08246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10089878 0.96 IDH1 (0.39) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10090022 0.94 IDH1 (0.37) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10089857 0.94 LMNA (0.39) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10089902 0.93 IDH1 (0.37) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10089879 0.92 CNR1 (0.41) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10089980 0.92 IDH1 (0.36) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL13085547 0.91 SLC2A1 (0.35) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL13085283 0.91 SLC2A1 (0.35) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10083881 0.91 SLC2A1 (0.35) IDH1CNR1SLC2A1SLC2A3SLC2A4
SCHEMBL10090010 0.91 TP53 (0.40) IDH1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791143-B2 Anthranilic diamide derivatives having cyclic side-chains BAYER CROPSCIENCE AG (DE) 2014-07-29 US disclosed
US-20120010249-A1 Anthranilic diamide derivatives having cyclic side-chains BAYER CROPSCIENCE AG (DE) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010249-A1 Anthranilic diamide derivatives having cyclic side-chains DDT, ADCY1, ANTXR2 IDH1 99/4885CNR1 984/4885SLC2A1 3782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.